Development of novel approaches to detect ovarian cancer recurrence

Abstract

Ovarian cancer is also known as the “silent killer” because this type of cancer spreads widely without the occurrence of any symptoms (1). Currently, ovarian cancer accounts for approximately 5% cancer deaths among women in the United States (2). Worldwide statistics from 185 countries indicated 295,414 new cancer cases and 184,799 deaths from this disease in 2018 (3). High-grade serous carcinoma is the most common histological type accounting for the majority of advanced ovarian cancers.